featured
Binimetinib in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
J. Clin. Oncol 2020 Aug 21;[EPub Ahead of Print], BJ Monk, RN Grisham, S Banerjee, E Kalbacher, MR Mirza, I Romero, P Vuylsteke, RL Coleman, F Hilpert, AM Oza, A Westermann, MK Oehler, S Pignata, C Aghajanian, N Colombo, E Drill, D Cibula, KN Moore, J Christy-Bittel, JM Del Campo, R Berger, C Marth, J Sehouli, DM O'Malley, C Churruca, AP Boyd, G Kristensen, A Clamp, I Ray-Coquard, I VergoteFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.